Physician profile
Douglas Lyle
NPI 1780776120
$9,939.97
in general payments reported to CMS, 2019-2025
37 companies · $12.79 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,929 · 2020: $1,419 · 2021: $2,632 · 2022: $1,890 · 2023: $666 · 2024: $391 · 2025: $12.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,070.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,069.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $2,948.07 | 2019-2022 | |
| Amgen INC. | $959.83 | 2019-2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $670.51 | 2019-2025 | Lifevest |
| Sanofi-Aventis U.S. LLC | $496.84 | 2019-2024 | |
| Astellas Pharma US INC | $426.90 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $398.03 | 2019-2023 | Xarelto |
| Amarin Pharma, INC. | $394.82 | 2019-2021 | |
| Abbott Laboratories | $381.65 | 2019-2023 | Jot Dx, Amplatzer Amulet, Cardiomems |
| Esperion Therapeutics, INC. | $368.34 | 2020-2024 | Nexletol |
| Pfizer INC. | $299.73 | 2019-2023 | |
| Cvrx, INC. | $276.48 | 2020-2023 | Barostim Neo System |
| Boston Scientific Corporation | $266.67 | 2019-2024 | |
| Novo Nordisk INC | $253.53 | 2022-2024 | Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.77 | 2019-2024 | Jardiance |
| Regeneron Healthcare Solutions, INC. | $192.66 | 2019-2021 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Lyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.